5'-hydroxypiroxicam
5'-hydroxypiroxicam structure
|
Common Name | 5'-hydroxypiroxicam | ||
|---|---|---|---|---|
| CAS Number | 77459-78-0 | Molecular Weight | 347.34600 | |
| Density | 1.636g/cm3 | Boiling Point | 627.1ºC at 760 mmHg | |
| Molecular Formula | C15H13N3O5S | Melting Point | N/A | |
| MSDS | USA | Flash Point | 333.1ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
[The binding of oxicam derivatives to human serum albumin].
Arzneimittelforschung 38(8) , 1089-92, (1988) The binding characteristics of several oxicam derivatives (tenoxicam, 4-hydroxy-2-methyl-N-phenyl-2H-1,2-benzothiazixine-3- carboxamide-1,1-dioxide (CP 14,304), 4-hydroxy-2-methyl-N-2-(3-methyl)-pyridyl-2H-1,2-benzothiazixine-3 -carboxamide- 1,1-dioxide (CP 1... |
|
|
High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5'-hydroxypiroxicam in human plasma and urine.
J. Chromatogr. A. 382 , 382-8, (1986)
|
|
|
Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography.
J. Chromatogr. A. 576(1) , 121-8, (1992) A simple and sensitive liquid chromatographic method with ultraviolet detection is described for the determination of the nonsteroidal anti-inflammatory drug piroxicam and its major metabolites in human plasma, urine and bile. Separation of these components o... |
|
|
Extractionless high-performance liquid chromatographic method for the simultaneous determination of piroxicam and 5'-hydroxypiroxicam in human plasma and urine.
J. Chromatogr. B, Biomed. Appl. 673(1) , 142-6, (1995) A simple and rapid (extractionless) high-performance liquid chromatographic method with UV detection, at 330 nm, was developed for the simultaneous determination of piroxicam and its major metabolite, 5'-hydroxypiroxicam, in human plasma and urine. Acidified ... |
|
|
Simultaneous determination of piroxicam and its major metabolite 5'-hydroxypiroxicam in human plasma by derivative spectrophotometry.
Analyst 123(8) , 1749-52, (1998) A first-derivative spectrophotometric method for the simultaneous determination of piroxicam (PX) and its major metabolite 5'-hydroxypiroxicam (OH PX) in human plasma is described. The method consists of direct extraction of the two drugs from the plasma samp... |
|
|
Determination of piroxicam and its major metabolite 5-hydroxypiroxicam in human plasma by zero-crossing first-derivative spectrophotometry.
J. Pharm. Biomed. Anal. 17(3) , 515-24, (1998) A zero-crossing first-derivative spectrophotometric method for the determination of piroxicam and its major metabolite 5-hydroxypiroxicam (5-HP) in human plasma is described. This technique permits the quantification of compounds with closely overlapping spec... |
|
|
Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam.
Eur. J. Clin. Pharmacol. 32(1) , 89-91, (1987) Piroxicam (20 mg once daily) was administered orally to six healthy young volunteers for 15 days. Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively. Piroxicam's plasma half-life (54.9 h) was significa... |
|
|
The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.
Br. J. Clin. Pharmacol. 37(1) , 1-5, (1994) 1. Piroxicam pharmacokinetics were assessed in three groups of subjects: (1) young healthy volunteers, (2) healthy elderly subjects (mean +/- s.d. creatinine clearance 88 +/- 13 ml min-1), and (3) elderly patients with renal insufficiency (creatinine clearanc... |
|
|
A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation.
Pharmacotherapy 12(2) , 93-7, (1992) We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect.... |